PhD

Dr. Liu has over 30 years of experience in cell biology research and translational research. He is a world-renowned expert in gene editing and cell therapy. He conducted postdoctoral and research work at Johns Hopkins University Howard Hughes Medical Institute and the California Institute of Technology, and served as a tenured professor at Texas A&M University, as well as a doctoral advisor at the University of Texas Houston Medical School and MD Anderson Cancer Center. Dr. Liu later joined East China Normal University, where he founded the Institute of Biomedical Sciences and served as Dean of the School of Life Sciences. He has published over 400 papers in top journals including Nature, Science, Cell, Nature Medicine, and Nature Biotechnology, together with over 300 patent applications and more than 150 patents granted. Dr. Liu has received the First Prize of the State Scientific and Technological Progress Award, and the gene editing and cell therapy research program he led has also been honored with the First Prize of the Shanghai Science and Technology Progress Award, as well as the China Outstanding Contribution Award for Translational Medicine. Since founding BRL Medicine in 2013, he has been dedicated to the development and clinical applications of gene editing and cell therapy technologies, providing patients with safe, effective, and widely accessible cell therapy products. Dr. Liu holds a doctoral degree from the University of Maryland at College Park.

PhD

Dr. Xiang has nearly 20 years of management experience in the pharmaceutical and healthcare industry. Prior to joining BRL Medicine, he held key leadership roles including President of Greater China at multinational pharmaceutical companies and CEO of innovative biopharmaceutical companies. He served successively as General Manager of Abbott Diabetes Care in Greater China and Emerging Asia, CEO of Shanghai RareStone Tech (Group) Co., Ltd., and President of Greater China at Santen Pharmaceutical, where he was responsible for business management and growth strategy formulation. Earlier in his career, Dr. Xiang also worked at Novartis and McKinsey & Company, Inc. He holds a bachelor's degree from Peking University and a doctoral degree from Yale University.

Mr. Jiang brings over two decades of experience in financial management, investment, financing, and capital markets. Prior to joining BRL Medicine, Mr. Jiang served as Chief Financial Officer for several life science and healthcare companies, including Zhejiang Haichang Biopharmaceutical Co., Ltd., Shanghai Newmed Medical Co., Ltd., and Fosun Kite Biotechnology Co., Ltd. (now known as Fosun Kerry (Shanghai) Biotechnology Co., Ltd.). He also held senior investment banking positions both domestically and internationally, including Managing Director at CCB International (Holdings) Limited and Principal at Piper Jaffray. He has been deeply involved in corporate financing, M&A, business development (BD), investor relations, and corporate governance. He has extensive first-hand experience in the Hong Kong capital markets and cross-border capital operations, and possesses a profound understanding of corporate management, financial management, and strategic execution for biotech companies. He holds a Bachelor of Medicine and Master of Medicine from West China University of Medical Sciences and an MBA from Columbia Business School.

PhD

Dr. Tan has over 10 years of research experience in the development and clinical translation of allogeneic CAR-T therapies. He has published multiple research papers as first author or co-author in prestigious journals including Cell, Nature, Molecular Therapy, and Cancer Research, and has filed several invention patents in China and overseas. Dr. Tan's research contributions have been recognized with the First Prize of the Shanghai Science and Technology Progress Award for 2024. He has also been designated as an "Elite Talent" and a "Leading Talent" under the Chunshen Talent Program of Minhang District in Shanghai. Dr. Tan holds a bachelor's degree from Jilin University and a doctoral degree from East China Normal University.

PhD

Dr. Zhang has long been engaged in research on tumor immunology and immune cell therapy, with a focus on the development of CAR-T therapies for solid tumors. She has successfully developed multiple innovative CAR-T cell products targeting solid tumors, including prostate cancer and gastric cancer, and has led research projects funded by the National Natural Science Foundation of China. Dr. Zhang holds a doctoral degree from East China Normal University.

PhD

Since joining BRL Medicine, Dr. Wang has been actively involved in the development and optimization of the company's R&D platforms and product candidates, and has collaborated with cross-functional teams to advance R&D projects. He has accumulated extensive hands-on experience in cell and gene therapy R&D, process development, quality control, and regulatory affairs. He has published multiple research papers in international academic journals, including The EMBO Journal and Cell Death Discovery. Dr. Wang holds a doctoral degree from the Center for Excellence in Molecular Cell Science, University of Chinese Academy of Sciences.